Medtronic’s ICM Proves Cost-Effective In Preventing Recurrent Stroke
A new study shows implantable cardiac monitors are a cost-effective tool for preventing recurrent strokes following a stroke suspected to be caused by atrial fibrillation.
You may also be interested in...
The randomized trial will evaluate the ability of the Reveal LINQ insertable monitor to help physicians prevent the progression of heart failure.
FDA Clears Medtronic's And Boston Scientific's Remote Cardiac Monitors, Approves Abbott’s Bluetooth-Compatible ICDs
Medtronic will launch the LINQ II remotely programmable, insertable cardiac monitor in the US and Europe this summer following FDA clearance. Boston Scientific plans to launch its LUX-Dx monitor later this year. The agency also approved Abbott's Gallant ICD and CRT-D devices, which communicate with Abbott's myMerlinPulse mobile app.
Innovation in arrhythmia monitoring technologies, as well as new research showing how these devices may improve arrhythmia diagnosis and management, particularly in cryptogenic stroke patients, will help drive growth in the market for outpatient ambulatory cardiac monitoring devices, which is valued at approximately $1.5 billion in the US alone.